| HS Code | 778945 |
| Product Name | Iodine Glycerol Teat Dip Veterinary Grade API |
| Product Type | Veterinary grade antiseptic/disinfectant active ingredient |
| Chemical Classification | Iodine-glycerol based antimicrobial complex |
| Physical State | Dark reddish-brown viscous liquid |
| Odor | Characteristic pungent iodine odor |
| Solubility | Miscible with water, ethanol, isopropanol, and glycerol |
| Iodine Assay | Typically 0.5% to 1.0% w/w for use as teat dip; concentrated API grades available with higher iodine content |
| Glycerol Content | Normally 2% to 20% w/w depending on formulation |
| Ph | Acidic, usually 3.0 to 5.5 |
| Specific Gravity | Approximately 1.10 to 1.30 at 25°C |
| Stability | Stable when protected from light; avoid alkaline conditions and reducing agents |
| Storage Conditions | Store in tightly closed, light-resistant containers in a cool, dry place |
| Shelf Life | 18 to 24 months when stored unopened under recommended conditions |
| Antimicrobial Spectrum | Broad-spectrum activity against bacteria, fungi, viruses, and spores |
| Irritancy Profile | Lower irritation potential when glycerol is present as an emollient |
As an accredited Iodine Glycerol Teat Dip Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Iodine Glycerol Teat Dip Veterinary Grade API is supplied in 25 L HDPE drums with tamper-evident closures and certificates of analysis. |
| Container Loading (20′ FCL) | Loaded in a 20′ FCL on palletized, sealed drums, safely secured, ventilated, and protected from moisture for transport. |
| Shipping | Ship as a regulated veterinary API in tightly sealed, light-resistant containers to prevent iodine sublimation and moisture uptake. Ensure compatibility with surfactants and avoid contact with metals or oxidizers. Use hazard labels for corrosion/irritation; maintain temperature stability, and document handling protocols as per national and international transport regulations. |
| Storage | Store in a cool, dry, well-ventilated area away from direct sunlight, heat sources, and moisture. Keep the container tightly sealed to prevent absorption of water and loss of iodine. Use corrosion-resistant materials; avoid contact with metals, oxidizers, and reducing agents. Maintain temperatures between 8–25°C. Ensure adequate ventilation and follow veterinary pharmaceutical storage protocols. |
| Shelf Life | Shelf life is 24 months from manufacturing date when stored in tightly sealed containers, protected from light and moisture, at controlled room temperature. |
The iodine-glycerol veterinary grade feedstock enters post-milking teat dipping as a concentrated iodophor in which free molecular iodine, triiodide, and hypoiodous acid coexist with glycerol as humectant and viscosity modifier. A concentrate containing 2.0–5.0% w/w available iodine is diluted with potable water to 0.5–1.0% w/w before application; at 20 °C the equilibrium between molecular iodine and triiodide shifts measurably when pH departs from 3.5–4.5. Production-scale mixing is performed in 316L stainless steel vessels with low-shear axial impellers operating at 300–600 rpm, and glycerol content is maintained at 20–40% w/w to achieve 30–70 mPa·s at 20 °C, which slows vertical run-off after cluster removal. Batch logs frequently record pH drift when source water alkalinity exceeds 150 mg/L as CaCO₃; the resulting post-dilution pH above 5.0 moves iodine speciation toward iodide and reduces the AOAC 960.09 suspension-test pass rate at 30 seconds contact against Staphylococcus aureus and Escherichia coli. Acid correction with phosphoric acid is therefore applied before the iodine-glycerol phase is added. Long-term storage above 50 °C promotes iodide oxidation and glycerol degradation, reducing total titratable iodine; storage tanks require vented HDPE or fluoropolymer-lined lids because free iodine vapour attacks carbon steel and polycarbonate. Efficacy testing is anchored to EN 1656:2019 and AOAC 960.09, with contact-time data recorded at 30 seconds and 5 minutes. Incompatibilities include amine-based surfactants and reducing sugars, which consume free iodine and generate non-antimicrobially active iodide before application.
| Parameter | Standard / Method | Control Range |
|---|---|---|
| Available iodine | Iodometric titration with 0.1 N sodium thiosulfate, USP Iodine monograph | 2.0–5.0% w/w concentrate; 0.5–1.0% w/w ready-to-use |
| Glycerol content | USP Glycerin monograph, refractive index at 20 °C | 99–101% anhydrous basis |
| Loss on drying | USP <731> | ≤ 2.0% |
| Uniformity of dosage units | USP <905> | AV ≤ 15 |
| Disinfectant efficacy | EN 1656:2019, AOAC 960.09 | Product label claim |
| Bacterial endotoxin in injectables | USP <85> | Product monograph limit |
For neonatal navel dipping of calves and lambs, the concentrate is diluted to 1.0–2.0% available iodine and viscosity is adjusted to 40–80 mPa·s at 20 °C, then applied through calibrated dip cups for a drain time of 10–15 seconds; pH is controlled to 3.5–5.0 and disinfectant efficacy is confirmed by AOAC 960.09 or EN 1656:2019 suspension methods.
Tablet and capsule manufacture from an iodine-glycerol feedstock is constrained by the non-compressible nature of the raw material. The feedstock is adsorbed onto anhydrous dicalcium phosphate or microcrystalline cellulose in a low-shear ribbon blender at 5–10 kg iodine-glycerol per 100 kg carrier, then wet-massed with purified water at 5–10% w/w and milled through a 1.0–1.5 mm oscillating granulator. Wet massing endpoint is defined by a 15–20% increase in granulator motor power draw from the dry-mix baseline, controlling granule porosity and subsequent drying rate. Drying in a fluid-bed dryer at inlet air ≤ 45 °C continues until loss on drying is ≤ 2.0% per USP <731>, because residual free molecular iodine sublimes from overheated granule surfaces above this threshold. Tablet compression is operated at 60–90 N hardness and friability is maintained below 1.0% per USP <1216>; capsules are filled to a target weight variation of ± 7.5% and evaluated by content uniformity per USP <905>. Lactose, native starch, and reducing-sugar excipients are excluded because they consume available iodine during accelerated storage, and magnesium stearate is limited to 0.5% w/w to avoid hydrophobic film formation that retards dissolution. Finished solid units are assayed by iodometric titration with 0.1 N sodium thiosulfate after extraction in 1.0 N sodium hydroxide.
The reduction step is carried out in glass-lined or 316L stainless steel reactors under a nitrogen blanket. Sodium metabisulfite 1.0–2.0% w/v is dissolved in demineralised water at 20–25 °C, and iodine-glycerol is added slowly with constant agitation to avoid local redox hotspots that entrain free iodine vapour. The endpoint is confirmed by iodometric titration with starch-free sodium thiosulfate 0.1 N; the pH is then adjusted to 6.5–7.5 with sodium hydroxide, and the solution is filtered through a 0.22 µm PVDF membrane into depyrogenated Type I glass vials. Terminal sterilisation at 121 °C for 15 minutes is validated to an F₀ value of 8–12 minutes, and bacterial endotoxin content is controlled per USP <85> to the monograph limit for the finished injection. Butyl rubber stoppers are overmolded or faced with fluoropolymer because residual iodine vapour attacks unprotected elastomers and generates particulate contamination during sterile storage.
Water-soluble powders and granules for drinking water or liquid feed delivery are produced by spraying the iodine-glycerol feedstock onto a sodium bicarbonate–potassium citrate carrier in a top-spray fluid-bed dryer. Inlet air temperature is kept at 38–45 °C, product temperature below 30 °C, atomisation pressure at 1.0–1.5 bar with a two-fluid nozzle, and final moisture is held below 0.8% by Karl Fischer titration per USP <921>. Granules are classified through 0.315–0.500 mm sieves and bulk density is adjusted to 0.75–0.95 kg/L by varying spray rate and air volume. Acidic carriers such as citric acid monohydrate are used only when matrix pH remains above 7.5 until reconstitution, because acidic conditions shift the iodine–iodide–triiodide equilibrium toward volatile molecular iodine and reduce total recoverable iodine. Reconstitution solubility is measured at 10 g/L in water at 25 °C with paddle agitation at 25 rpm; the target residual free iodine for livestock drinking water is 1–2 ppm after 5 minutes.
The feed premix application is applied by spraying iodine-glycerol onto ground limestone or calcium carbonate carriers inside a horizontal paddle mixer. The spray rate is controlled at 0.5–1.0 kg/min per 1000 kg carrier, mixer speed maintained at 20–40 rpm for 8–12 minutes, and iodine distribution is verified by iodometric titration on 10 representative samples with a coefficient of variation below 5.0%. Trace mineral interactions are monitored because ferrous sulfate reduces iodine to iodide while copper sulfate can re-oxidise iodide to molecular iodine; both pathways accelerate assay drift when premix pH falls below 5.0. Selenium-containing materials are introduced only after iodine-glycerol has been fully adsorbed, as selenite oxidises iodide back to molecular iodine and reduces recovery in subsequent extraction. Finished premix storage is limited to 6 months at 25 °C and 60% RH unless a metallised polyethylene liner is used; moisture ingress above 0.5% promotes iodine migration to headspace and particle caking.
For footbath and skin wound flushing, a 1.0% available iodine intermediate is first prepared from the concentrated feedstock and then diluted 1:50 to 1:100 with potable water to yield 100–200 ppm free iodine. The solution is circulated through rubber-lined boot baths and drained after 400–600 animal passes, with residual iodine monitored by DPD or iodometric field kits. Topical wound spray solutions are formulated at 0.5% available iodine and packaged in amber HDPE bottles with pin-stream sprayers; contact time for bacterial reduction is 30 seconds under EN 1656:2019 suspension conditions. Prolonged air exposure generates iodine vapour that degrades polycarbonate spray heads unless fluoropolymer or polypropylene internals are specified.
Competitive Iodine Glycerol Teat Dip Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Supplied as a dark amber, viscous liquid, Iodine Glycerol Teat Dip Veterinary Grade API is a non-sterile active substance intermediate composed of molecular iodine dispersed in glycerol with controlled water content. The material is released for veterinary drug product manufacturing rather than direct application as a post-milking barrier; ready-to-use teat dips are downstream dilutions containing surfactants, skin conditioners, and pH buffers. Supplier identification is assigned through batch-specific specification codes that encode the iodine-to-glycerol ratio and solvent class. Procurement documentation should therefore reference the applicable residual solvent profile and elemental impurity certificate, not a single universal model designation.
The API grade functions as a stabilized iodine reservoir. Its use in tablets, injections, capsules, powders, granules, premixes, and solutions arises from the gradual release of molecular iodine upon dilution or matrix hydration. Because glycerol acts as both solvent and humectant, the product exhibits lower vapour pressure than alcoholic iodine solutions and does not introduce polyvinylpyrrolidone residues when compared with povidone-iodine. Supplier model codes are not harmonized; some vendors designate ready-to-dilute iodine glycerol as a 1.0% I2/glycerol class and a concentrate as a 5.0% I2/glycerol class. These codes are concentration identifiers rather than universal product specifications.
The principal differences are carrier chemistry, free-iodine activity, and viscosity. Povidone-iodine binds molecular iodine in a polyvinylpyrrolidone complex, releasing free iodine slowly and requiring a hydration step for full activity; the complex contributes polymer-associated viscosity and can leave film residue on mixing equipment. Alcoholic iodine solutions provide rapid iodine release but introduce ethanol or isopropanol, which limits use in powders and premixes because of residual solvent classification under VICH GL18. Iodine glycerol, by contrast, delivers iodine in a water-miscible glycerol matrix with a typical viscosity of 150–400 mPa·s at 25 °C as measured by ASTM D2196. The free-iodine reservoir in glycerol is not polymer-bound; therefore assay values reflect total titratable iodine rather than only dialyzable iodine. This distinction matters when correlating release test results with antimicrobial activity.
Release testing for a non-sterile veterinary API should follow the supplier’s pharmacopoeial-style specification. The values below represent commonly controlled parameters; individual suppliers may set tighter limits based on stability data and intended downstream dosage form.
| Parameter | Typical release criterion | Test method or standard |
|---|---|---|
| Appearance | Dark amber to amber-brown viscous liquid | Visual inspection |
| Available iodine, ready-to-dilute grade | 0.95–1.05% w/w | Iodometric titration with 0.1 N sodium thiosulfate |
| Available iodine, concentrate grade | 4.0–5.0% w/w | Iodometric titration |
| Glycerol content | 70.0–90.0% w/w | Gas chromatography or refractive index |
| Water content | ≤15.0% w/w | Karl Fischer titration, USP <921> |
| pH, 10% aqueous dilution | 3.5–6.0 | USP <791> |
| Density at 20 °C | 1.25–1.35 g/mL | ASTM D4052 |
| Viscosity at 25 °C | 150–400 mPa·s | ASTM D2196 |
| Elemental impurities | Lead ≤0.5 µg/g; arsenic ≤1.5 µg/g; cadmium ≤0.5 µg/g | USP <232>/<233> |
| Residual solvents | Class 3 solvents ≤0.5% w/w | VICH GL18 |
| Microbial limits | TAMC ≤100 CFU/g; TYMC ≤10 CFU/g; absence of Salmonella and Escherichia coli | USP <61>/<62> |
Stability is governed primarily by water activity, trace metal contamination, and headspace oxygen. In concentrated glycerol matrices, water activity below 0.60 suppresses triiodide formation and slows iodine loss, but when the product is diluted into aqueous formulations above 1:10, the equilibrium shifts toward free iodine and hypoiodous acid in a pH-dependent manner. Formulations buffered above pH 7.0 should be avoided because disproportionation accelerates and available iodine is lost as iodide and iodate. Production-scale handling in jacketed 316L stainless-steel vessels indicates that nitrogen blanketing and storage at 15–25 °C are necessary to maintain assay within release range over 12 months; published data for this specific configuration is limited.
Trace iron and copper ions catalyse iodide oxidation and should be controlled below 1 mg/kg in the final container. If the material contacts non-passivated stainless steel, a chelating agent such as disodium edetate may be required at 0.01–0.05% w/w in the diluted formulation. For long-term storage, containers should be light-resistant and closed under nitrogen headspace in accordance with general packaging requirements such as USP <659>; natural rubber closures are incompatible because iodine absorption is significant. Lot-to-lot variance arises from iodine sublimation during bulk charging, water content drift in open vessels, and incomplete homogenisation if the mixing impeller is not operated under vacuum. Samples should be drawn from top, middle, and bottom levels and assayed by iodometric titration; homogeneity acceptance is typically ±5% relative standard deviation.
In high-shear dispersion for powders and premixes, the liquid is metered at 2–5% w/w onto a carrier such as lactose monohydrate or corncob grits in a horizontal ploughshare mixer. Mixing time beyond 10–15 min at impeller tip speed above 8 m/s heats the bed and produces localized iodine sublimation. Contact surfaces should be 316L stainless steel or glass-lined; copper and brass components are incompatible. For medicated feed premixes, the iodine glycerol is usually first diluted to a 10% w/w iodine-glycerol intermediate on calcium carbonate or silica carrier before blending; the mixer should operate at 15–25 rpm to avoid shear-induced heat.
The liquid API is not suitable for direct compression. It is first adsorbed onto a compressible carrier or incorporated into a binder solution for wet granulation. In a fluid-bed granulator fitted with a top-spray nozzle, the iodine glycerol solution is diluted to 10–20% w/w solids/liquid and sprayed at product temperature 30–40 °C. Granule loss on drying should remain between 1.0% and 3.0% w/w; over-drying below 1.0% water reduces compressibility, while residual moisture above 3.0% can cause punch filming during compression. For capsules, the dried granules are filled into hard gelatin or HPMC shells at relative humidity below 40%; higher humidity increases tackiness and iodine migration into the shell.
Wet granulation with twin-screw extrusion is possible but less common. A twin-screw extruder with L/D 40:1 and segmented screws can be used at 150–300 rpm with barrel temperatures set below 45 °C; published data for this specific configuration is limited. Tablet disintegration acceptance should be verified by USP <701> and tablet breaking force by USP <1217> because the glycerol component may soften tablets if content exceeds 5% w/w of the core.
Direct combination with strong reducing agents should be avoided; ascorbic acid, sodium metabisulfite, sodium thiosulfate, and cysteine reduce molecular iodine to iodide within minutes at aqueous pH 4–6 and abolish antimicrobial activity. In premixes containing amine-bearing feed additives, molecular iodine may react with primary amines to form iodamines, which have different stability and may contribute to odour. Because published data for this specific configuration is limited, compatibility screening should be performed by iodometric titration after 24 h of storage at 40 °C/75% RH in the intended packaging.
| Product class | Carrier or complex | Typical viscosity at 25 °C | Application limitation |
|---|---|---|---|
| Iodine glycerol teat dip API | Glycerol-water | 150–400 mPa·s | Avoid reducing agents; not sterile; moisture-sensitive powders require carrier pre-blend |
| Povidone-iodine | Polyvinylpyrrolidone complex | 5–20 mPa·s for 10% solution | PVP residue; slower free-iodine release |
| Alcoholic iodine solution | Ethanol or isopropanol-water | 2–5 mPa·s | Residual solvent load and flammability; unsuitable for powders and premix |
| Strong iodine solution | Potassium iodide-water | 1–3 mPa·s | Higher iodide load; lower humectant property |
For injectable or intramammary preparations, a parenteral-grade qualification of the same chemical form is required. Non-sterile API should not be introduced into aseptic filling without depyrogenation; endotoxin content, if not vendor-controlled, must be removed by validated ultrafiltration or activated carbon treatment. In aqueous solution manufacturing, the product is diluted to the target available iodine concentration, typically 0.05–0.3% w/w for topical irrigation or intramammary preparations, then filtered through a 0.2 µm sterilizing filter. Because iodine can attack polytetrafluoroethylene seals at high concentration, filter compatibility with the final diluted solution should be qualified under worst-case contact time. Steam sterilization of concentrated iodine glycerol is not recommended because iodine volatilizes; if terminal sterilization is required, the diluted solution should be filter-sterilized and aseptically filled.
For oral solutions and drinking-water premixes, dilution is generally 1:500 to 1:2000, and the resulting solution should be consumed within 24 h if stored in open tanks, because light and air reduce available iodine. Glycerol in the formulation reduces evaporation and improves dispersion compared with alcoholic iodine concentrates. Cleaning of processing equipment uses warm water and dilute sodium thiosulfate solution 0.5–1.0% w/w to reduce iodine residues, followed by 0.1 N sodium hydroxide wash; phenol-based disinfectants should be avoided because they can form odorous iodophenols. Quality release should include a certificate of analysis, certificate of origin, residual solvent declaration, elemental impurity statement, and microbial and endotoxin statements where applicable. For veterinary API supplied for further processing, compliance with 21 CFR 211 or equivalent local GMP is expected; laboratory support should operate under ISO 17025 or equivalent.
